Profile avatar
ats-pitb.bsky.social
59 posts 81 followers 62 following
Prolific Poster

🧬TB doesn’t end with treatment. New US study reveals life expectancy after TB diagnosis was 2 years shorter for TB cohort compared to non-TB cohort. We need to rethink what “cured” really means. 📉🫁 #Tuberculosis #PublicHealth www.atsjournals.org/doi/full/10....

Great PITB session on pulmonary viral infections across lifespan! More exciting sessions to come! #ATS2025

3 bottle system of pleural drainage in real time! Join the #ATS2025 Teaching Competition in the Marriott J right now!

🔥Happening now: ATS Teaching Competition at Marriott Pacific J (4th floor). Join us for some excellent education!!! #ATS2025 @atscommunity.bsky.social @ats-assemblies.bsky.social

Happening now: Charles Dela Cruz talking about predisposition to COPD and viral infections. Join us at Moscone West 2001 #ATS2025 @atscommunity.bsky.social @ats-assemblies.bsky.social

♨️♨️♨️ Don't miss out!! Join us at Moscone West Room 2001/2003 for Symposium on Pulmonary Virus Infections Across the Lifespan. Discover latest science on host-virus interaction! Session info here: ats2025.d365.events/directory/se... #ATS2025 @atscommunity.bsky.social @ats-assemblies.bsky.social

Congratulations to the ATS PITB 🌟🌟🌟Peer Recognition Awardees 🌟🌟🌟 Dr. Katrina Traber (Early Career), Dr. Barbara Jones (Mid Career) and Dr. Kristina Crothers (Senior-Level Peer Recognition)! What an inspiring group! #ATS2025 @atscommunity.bsky.social @ats-assemblies.bsky.social

Congratulations to our PITB🌟🌟🌟RISING STARS🌟🌟🌟 Dr. Merete Long and Dr Taylor David Coston!! #ATS2025 @atscommunity.bsky.social @ats-assemblies.bsky.social @atsearlycareer.bsky.social

Congratulations to PITB Abstract Awardees!#ATS2025

Happening now: PITB Assembly Meeting! Join us at Moscone West Room 3000! #ATS2025

📢📢📢Join us for the ATS PITB Assembly Membership Meeting tonight 5 - 7 p.m. at the Moscone Center Room 3000/3002/3004 (West Building, Level 3)! #ATS2025

Happening now: Join us at Moscone South Room 209-211 to learn about host directed therapies! #ATS2025 @atscommunity.bsky.social @ats-assemblies.bsky.social

#ATS2025 is here!!! Looking forward to many exciting Pulmonary Infections and Tuberculosis sessions! Check out our 🗞️Newsletter🗞️ to find a full list of PITB sessions! @ats-assemblies.bsky.social @atscommunity.bsky.social

♨️♨️♨️ Hot of the press: Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis www.nature.com/articles/s41...

🔥 🔥 🔥 Hot of the press: Broad Immunomodulatory Effects of the Dipeptidyl Peptidase-1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW Trial Article here: buff.ly/2HsFkW7 Related editorial here: buff.ly/fHEPmaY

🗳️ ATS Members: Your Voice Matters! The 2025 ATS Leadership Election is underway. Cast your vote FOR or AGAINST the proposed slate by May 10. 📅 Results announced: May 12 🔗 Vote now: site.thoracic.org/about-us/lea... #ATSElections #PulmonaryLeadership

🔥🔥🔥 Hot of the press: Global, Regional, and National Burden of Pulmonary Fungal Infections 1990-2021 🍄🍄🍄 See pre-print here: www.atsjournals.org/doi/abs/10.1... @idsainfo.bsky.social @btsrespiratory.bsky.social @atscommunity.bsky.social

Meet our ATS PI-TB Assembly Mid-Career Highlight, Dr. O'Neil Green. Dr. Green's research seeks to improve the care of patients with 🦠 non-CF bronchiectasis and NTM disease. 🫁

🔥 🔥 🔥 Hot of the press: Risk factors for drug-resistant pathogens in community-acquired pneumonia: systematic review and meta-analysis buff.ly/7bAJkwb @idsainfo.bsky.social @atscommunity.bsky.social

Tune into one of the webinars on TB for #WorldTBDay2025! @theunion-tblh.bsky.social @idsainfo.bsky.social @atscommunity.bsky.social @who.int #MedSky #EndTBNow 3/24 730CST Yes! We Can End TB WHO/PAHO buff.ly/70ihkKf 3/25 1830CST ATS/CHEST/SEPAR/ALAT Hot Topics in Tuberculosis buff.ly/ywLJbov

Today is World Tuberculosis Day. This year's theme is "We can end TB: Commit, Invest, Deliver." Our very own @ats-pitb.bsky.social works to help learn more and work to ending this disease!

In a phase 2B trial of HIV-negative adults successively treated for drug susceptible pulmonary TB, the H56:IC31 tuberculosis vaccine was well tolerated and immunogenic, but did not reduce the risk of recurrent tuberculosis.

The International Union Against TB and Lung Diseases offers coursework including open-access online modules for the TB community. buff.ly/YJvpl7g

Severe respiratory viral infections impair peroxisomes in macrophages, worsening lung inflammation and tissue damage post-COVID-19. Boosting peroxisome function may be a promising therapy for reducing complications of viral respiratory infections.

🔥 🔥 🔥 Our @ATS_PITB Winter Highlights Newsletter is now available online! Find out about the newest ATS Workshop on TB, read about upcoming Webinar on #WorldTBDay2025 and find out what our Early Career Stars are doing! buff.ly/25ysCcA @atscommunity.bsky.social

📣 Join us next week for #WorldTBDay2025 ! @atscommunity.bsky.social @idsainfo.bsky.social @theunion-tblh.bsky.social #MedSky WHO World TB Day 3/24 730CST buff.ly/CB2E0s0 Yes! We Can End TB (WHO/PAHO) 3/25 0900CST buff.ly/ScRnXVx ATS/CHEST/SEPAR/ALAT Webinar 3/25 1830CST buff.ly/xZJGmUu

🔥 🔥 🔥 Hot of the press: Cardiovascular benefits and safety profile of macrolide maintenance therapy in patients with bronchiectasis buff.ly/CGXv34s

ATS Secretary Michelle Ng Gong, MD, ATSF and staff are standing up for science for thousands of our members impacted by federal policies which are crushing lung research. #NYC #standupforscience @standupforscience.bsky.social

Meet our @ATS_PITB Assembly Early Career Highlight, Dr. Jezreel Pantaleón García. Dr. Garcia's research focuses on developing translational models of 🦠 pulmonary infections. 🫁

Happy to again co-chair the American Thoracic Society Conference Post-Grad Course "A Hands-On Introduction to Studying the Lung Microbiome" with Bob Dickson and Leo Segal in San Francisco on May 16! Register here: tinyurl.com/Lung-microbi... @ats-pitb.bsky.social

🔥🔥🔥 Hot of the press: Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older: results from two randomised, active-controlled, phase 3 trials buff.ly/leEyerJ #cysticfibrosis #MedSky #pccmsky

💡 Stay informed! Explore the latest ATS resources on measles, and tune into the new #BreatheEasy podcast discussing vaccine hesitancy here: https://buff.ly/4gXR34J #VaccinesSaveLives #MedSky #pulmsky @idsainfo.bsky.social @btsrespiratory.bsky.social

Hsu et al. discovered a neutrophil-derived extracellular vesicle which outlives neutrophils and regulates complement to modulate inflammation. https://buff.ly/3D2WnGd

Stay up-to-date on Avian influenza A with resources from IDSA for patients and clinicians.

♨️♨️♨️ Hot of the press: Contribution of Post-TB Sequelae to Life-Years Lost from TB Disease in the United States www.atsjournals.org/doi/abs/10.1... Post-TB lung disease increases mortality of TB survivors everywhere, including US! #EndTB #medsky @atscommunity.bsky.social @idsainfo.bsky.social

🚨 Assembly Leadership Vote 2025 - Cast Your Vote Today!🚨 Vote for the future leaders of your Assembly! 🗳️ Head over to the ATS Website to cast your vote online. The deadline to vote is Monday, February 17th, 2025. www.thoracic.org/vote/assembl...

⏰⏰⏰ HAPPENING NOW! Join in to learn more about #bronchiectasis management from our experts Dr. Chalmers and Dr. Aksamit in ATS PITB PINE Webinar! thoracic.zoom.us/meeting/regi...

The American Thoracic Society shares this opinion. www.acponline.org/acp-newsroom...

The ATS applauds 22 state attorneys general in challenging NIH medical research funding cut. Friday's NIH action to cut life-saving medical research is prohibited by law. www.nbcboston.com/news/local/n...

⏰⏰⏰ Only two days left! Don't miss out on learning about latest #bronchiectasis management with @ProfJDChalmers and Dr. Timothy Aksamit! Sign up below!

⏰DON'T MISS OUT⏰ - ATS 2025 Bear Cage Competition: 2/10 bit.ly/4hEOh5g - 🌲PINE🌲Webinar on PROMIS I&II trials: 2/13 11 CST bit.ly/40YBa9A - Teaching Competition: 2/14 bit.ly/4hoBtjC - Assembly Elections: 2/17 bit.ly/3Epms2C @ats-assemblies.bsky.social

February 13 at 12pm Eastern Join @ats-pitb.bsky.social Journal Club The Efficacy & Safety of Colistimethate Sodium Delivered Via I-neb in Patients w/ Bronchiectasis & Pseudomonas aeruginosa Infection: PROMIS-I & PROMIS-II Randomized Controlled Trials Register here: thoracic.zoom.us/meeting/regi...

♨️♨️♨️ Hot of the press: Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis | New England Journal of Medicine www.nejm.org/doi/full/10....

♨️⁉️Did #PROMIS deliver on it's promise⁉️Find out in our🌲 PINE🌲Webinar next week! We will discuss PROMIS-I and PROMIS-II RCT with @profjdchalmers.bsky.social and Dr. Aksamit #bronchiectasis #medsky #PCCMsky @ats-assemblies.bsky.social @atsearlycareer.bsky.social 📅 Feb 13 11 AM CT 🗒️ bit.ly/40YBa9A

CERTAIN study analysis of 2,253 ventilated patients from 11 LMICs & 5 HICs: Patients in LMICs face 2x higher VAP risk. Staffing shortages & prolonged ventilation, not bundle adherence, were key drivers. https://buff.ly/3Cm165A

Serotype 3 is now the dominant cause of pneumococcal pneumonia in adults, despite childhood vaccines. Pneumococcal CAP cases nearly doubled over the past decade (2013–2023). https://buff.ly/4hxxmBs

Clinical Characteristics and Prognosis of Patients With Severe Pneumonia With Pneumocystis jirovecii Colonization - CHEST journal.chestnet.org/article/S001...